Phase II trial of irinotecan/gemcitabine as second-line therapy for relapsed and refractory small-cell lung cancer: Cancer and Leukemia Group B Study 39902.
- Citation:
- Ann Oncol vol 18 (2) 331-7
- Year:
- 2007
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Book Volume:
- Parents:
- None
- Children:
- None
- Program:
- OGC
- Primary Committee:
- Respiratory
- Sec. Committees:
- Pharmas:
- Grants:
- CA02599, CA03927, CA08025, CA21060, CA31946, CA32291, CA33601, CA35091, CA41287, CA45808, CA47555, CA47559, CA47577, CA47642, CA77298, CA77406, CA77658
- Corr. Author:
- Authors:
- C M Rocha-Lima J E Herndon M E Lee J N Atkins A Mauer E Vokes M R Green
- Networks:
- Study
- CALGB-39902
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 2
- Keywords:
- Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Camptothecin, Carcinoma, Small Cell, Deoxycytidine, Female, Humans, Lung Neoplasms, Male, Maximum Tolerated Dose, Middle Aged, Neoplasm Recurrence, Local, Prognosis, Salvage Therapy, Survival Rate